

4 th International Symposium on Uro-Oncology – hybrid

State-of-the-Art lectures
debates and Semi-Live-Surgeries

April 29/30 2022

Radisson blu hotel cologne

simultaneous
translation
german
english



UNIKLINIK
KÖLN



Center for Integrated Oncology
Aachen Bonn Cologne Duesseldorf



OTTO VON GUERICKE
UNIVERSITÄT
MAGDEBURG



MEDIZINISCHE FAKULTÄT

Dear esteemed colleagues,

it is our pleasure to cordially inviting you to the 4th International Symposium on Uro-Oncology to be held in Cologne, Germany on April 29 and 30, 2022. Due to the Corona situation with increasing numbers of infections, we had to postpone the meeting which was originally scheduled as a real face-to-face meeting on December 3 and 4, 2021.

As in recent years, the symposium is composed of State-of-the-Art lectures, pro and con debates, semi live surgeries and interactive as well as interdisciplinary case discussions. All the presentations are done by an excellent faculty of well known national and international experts in the field of uro-oncology. The focus of the symposium is to deliver newest developments in local and systemic therapy of urogenital malignancies which certainly will be integrated in upcoming guidelines. We have identified those topics which are highly relevant for daily routine and which very often result in controversial discussions among urologists, oncologists and radiation oncologists.

We hope that the content of our symposium will provide you with an excellent update on current developments in uro-oncology. We would be more than happy to welcoming you in Cologne, to performing fruitful discussions and last but not least to experiencing a personal reunion.

Besides the face-to-face meeting we also have organized a hybrid symposium so that you might participate without travelling. We also provide you with a simultaneous translation German to English and vice versa so that you might participate in any discussion.

We remain with warmest regards and we are looking to seeing you in Cologne.



**Prof. Dr. med.
Axel Heidenreich**
Director and Chairman
Department of Urology,
uro-oncology and robot
assisted surgery
University hospital of Cologne

**Prof. Dr. med.
Martin Schostak**
Department of Urology,
Medical Faculty University of
Magdeburg

Program

Friday April 29, 2022

09:00 Welcome

Axel Heidenreich, Cologne (GER)
Martin Schostak, Magdeburg (GER)

» Risk adapted and individualized early detection of prostate cancer – what do we need?

Moderation: Martin Schostak, Magdeburg (GER),
Frank König, Berlin (GER)

09:10 Introduction

Daniel Eberli, Zürich (CH)

09:15 Optimal, individualized use of PSA is the way to go

Peter Albers, Düsseldorf (GER)

09:25 Multiparametric MRI is sufficient for proper diagnosis

Heinz Schlemmer, Heidelberg (GER)

09:36 Biomarker and MRT represents the best combination

Jan Philipp Radtke, Düsseldorf (GER)

09:45 Case discussion

» Prostate Cancer – radical prostatectomy

Moderation: Matthias Saar, Aachen (GER),
Judd W. Mou, Durham (USA)

10:00 Transperitoneal nerve sparing RALP

Florian Hartmann, Cologne (GER)

10:05 Extended retropubic radical prostatectomy for locally advanced cT3 PCa

Judd W. Moul, Durham (USA)

10:10 Peritoneal flap to prevent symptomatic lymphoceles

n.n.

10:15 Which is the optimal indication for extended pelvic lymphadenectomy at time of radical prostatectomy?

Axel Heidenreich, Cologne (GER)

10:25 Discussion

10:40 STATE-of-the-ART: nightmares of radical prostatectomy – what I will never do again

Jeff Karnes, Rochester (USA)

Astellas Pharma AG

10:55 Systemic therapie of mHSPC – current data and recommendations

Andres Jan Schrader, Münster (GER)

11:40 Coffee Break

» Muscle invasive urothelial carcinoma of the urinary bladder: cystectomy versus bladder preservation

Moderation: Axel Heidenreich, Cologne (GER),
Anja Lorch Zurich (SUI)

12:30 Case presentation: pT2a, 2.5cm, kein CIS

12:35 Immediate radical cystectomy is the treatment of choice

Günter Niegisch, Düsseldorf (GER)

12:42 Neoadjuvant chemotherapy/immunological therapy is the treatment of choice

Cora Sternberg, New York (USA)

12:49 Brachytherapy represents the treatment of choice

Laura Mertens, Amsterdam (NL)

12:56 pT0 following neoadjuvant chemotherapy

13:01 radical cystectomy remains treatment of choice

Mauricio Brausi, Modena (I)

13:08 Wait-and-See represents the best option

Joachim Noldus, Herne (GER)

13:15 Case discussion

Program

Friday April 29, 2022

» Semi-Live-Surgery: urinary diversion – done right

Moderation: Peter Albers, Düsseldorf (GER),
Mauricio Brausi, Modena (IT)

13:30 Ileum conduit, ureterocutaneostomy

Armin Pycha, Bozen (SUI)

13:40 Order lands of urinary diversion

Wilhelm Hübner, Korneuburg (AU)

13:50 Orthotopic ileal neobladder

Arnulf Stenzl, Tübingen (GER)

14:00 Discussion

Bristol-Myers Squibb GmbH & Co. KG

14:10 Immune-oncological therapy in muscle invasive bladder cancer

› Status Quo – chemotherapy

n.n.

› Quo Vadis – immuno-oncological therapy

n.n.

› At the end of Latin?...

What do we do out of it?

n.n.

n.n.

14:45 Coffee Break

» progressive, metastatic castration resistant prostate cancer following ARTA and docetaxel

Moderation: Martin Schostak, Magdeburg (GER)
David Pfister, Cologne (GER)

15:30 Cabazitaxel is the primary option

Cora Sternberg, New York (USA)

15:35 ¹⁷⁷Lu-PSMA always prior to cabazitaxel

Frederik Verburg, Rotterdam (NL)

15:40 Olaparib is the first choice

David Pfister, Cologne (GER)

15:45 Case discussion

» Multimodality Treatment of locally advanced prostate cancer

Moderation: Robert Tauber, Munic (GER),
Isabel Heidegger, Innsbruck (AU)

16:15 Always start with radical prostatectomy

Jeff Karnes, Rochester (USA)

16:20 Always start with radiation therapy

Simone Marnitz-Schulze Cologne (GER)

16:25 Neoadjuvant systemic therapy followed by local therapy represents the first step

Vsevolod Matveev, Moscow (RUS)

16:30 Case discussion

» Non-muscle invasive urothelial carcinoma of the urinary bladder

Moderation: Günter Niegisch, Düsseldorf (GER),
Manuel Ritter, Bonn (GER)

17:00 STATE-of-the-ART: What is new in the management of BCG-refractory non-muscle invasive bladder cancer?

Gero Kramer, Wien (AU)

» Semi-Live-Surgery

17:15 TUR-B done right: the standard approach

Mauricio Brausi, Modena (I)

17:25 EN-bloc resection done right is the future

Christian Schwentner, Stuttgart (GER)

17:35 Case discussion

18:00 End of Day 1

Program

Saturday April 30, 2022

» Renal Cell Carcinoma: small renal mass

Moderation: Pilar Laguna, Istanbul (TK)

Vsevolod Matveev, Moscow (RUS)

08:30 Introduction

Andres Schrader, Münster (GER)

08:35 PRO active surveillance?

Peter Goebell, Erlangen (GER)

08:40 PRO organ sparing surgery

Vsevolod Matveev, Moscow (RUS)

08:45 PRO focal therapy

Pilar Laguna, Istanbul (TK)

08:50 Case Discussion

» Oligometastatic Renal Cell Carcinoma

Moderation: Peter Goebell, Erlangen (GER),

Christian Pallasch, Cologne (GER)

09:15 Systemic therapy represents the best approach

Thomas Steiner, Erfurt (GER)

09:20 Interventional radiation therapy is the treatment of choice

Gert de Meerler, Leuven (NL)

09:25 Surgical Resection remains the best option

Markus Kuczyk, Hannover (GER)

09:30 Case Discussion

Ipsen Pharma GmbH

10:00 Future perspectives in the management of mRCC – 1 st. line combination Therapie with Cabozantinib & Nivolumab: The new standard approach

n.n.

n.n.

10:50 Coffee Break

» Hot Topics in Uro-Oncology: adjuvant treatment of locally advanced urogenital cancer

Moderation: Gero Kramer, Wien (AU),

Martin Schostak, Magdeburg (GER)

Muscle invasive bladder cancer following radical cystectomy

11:30 Current Evidence

Robert Tauber, Muenic (GER)

11:37 Pro

David Pfister, Cologne (GER)

11:44 Contra

Mauricio Brausi, Modena (I)

Urothelial cancer of the upper urinary tract

12:00 Aktuelle Studienlage

Anja Lorch, Zurich (SUI)

12:07 Pro

Pia Paffenholz, Cologne (GER)

12:14 Contra

Vsevolod Matveev, Moscow (RUS)

12:21 Discussion

Prostate Cancer following radical prostatectomy

12:30 Aktuelle Studienlage

Isabel Heidegger, Innsbruck (AU)

12:37 Pro

Daniel Eberli Zurich (SUI)

12:44 Contra

Judd W. Moul, Durham (USA)

Janssen-Cilag GmbH

13:00 Visionary outlook meets practical insight in metastatic prostate cancer

Stefan Machtens, Bergisch Gladbach (GER)

Robert Tauber, München (GER)

13:45 Summary and Adjourn

14:00 End of the symposium

Speakers

- › Prof Dr. Peter Albers, Düsseldorf (GER)
- › Prof. Dr. Mauricio Brausi, Modena (IT)
- › Prof. Dr. Daniel Eberli, Zurich (SUI)
- › Prof. Dr. Peter Goebell, Erlangen (GER)
- › Dr. Florian Hartmann, Cologne (GER)
- › Prof. Dr. Isabel Heidegger, Innsbruck (AU)
- › Prof. Dr. Axel Heidenreich, Cologne (GER)
- › Prof. Dr. Wilhelm Hübner, Korneuburg (AU)
- › Prof. Dr. Jeff Karnes, Rochester (USA)
- › Prof. Dr. Gero Kramer, Wien (AU)
- › Prof. Dr. Frank König, Berlin (GER)
- › Prof. Dr. Markus Kuczyk, Hannover (GER)
- › Prof. Dr. Pilar Laguna, Istanbul (TK)
- › Prof. Dr. Anja Lorch, Zurich (SUI)
- › Prof. Dr. Vsevolod Matveev, Moscow (RUS)
- › Dr. Stefan Machtens, Bergisch Gladbach (GER)
- › Prof. Dr. Simone Marnitz-Schulze, Cologne (GER)
- › Prof. Dr. Gert de Merler, Leuven (GER)
- › Dr. Laura Mertens, Amsterdam (NL)
- › Prof. Dr. Judd W. Moul, Durham (USA)
- › Prof. Dr. Günter Niegisch, Düsseldorf (GER)
- › Prof. Dr. Joachim Noldus, Herne (GER)
- › Priv.-Doz. Dr. Pia Paffenholz, Cologne (GER)
- › Prof. Dr. Christian Pallasch, Cologne (GER)
- › Prof. Dr. David Pfister, Cologne (GER)
- › Prof. Dr. Armin Pycha, Bozen (IT)
- › Priv.-Doz. Dr. Jan-Philipp Radtke, Düsseldorf (GER)
- › Prof. Dr. Manuel Ritter, Bonn (GER)
- › Prof. Dr. Matthias Saar, Aachen (GER)
- › Prof. Dr. Heinz Schlemmer, Heidelberg (GER)
- › Prof. Dr. Martin Schostak, Magdeburg (GER)
- › Prof. Dr. Andres Schrader, Münster (GER)
- › Prof. Dr. Christian Schwentner, Stuttgart (GER)
- › Prof. Dr. Thomas Steiner, Erfurt (GER)
- › Prof. Dr. Arnulf Stenzl, Tübingen (GER)
- › Prof. Dr. Cora Sternberg, New York (USA)
- › Dr. Robert Tauber, Munic (GER)
- › Prof. Dr. Frederik Verburg, Rotterdam (NL)

Sponsoring

- › Apogepha Arzneimittel GmbH (3.000 €)
- › Astellas Pharma GmbH (20.000 €)
- › AstraZeneca GmbH (6.000 €)
- › Bayer Vital GmbH (6.000 €)
- › bk Medical Medizinische Systeme GmbH (1.500 €)
- › Bristol-Myers Squibb GmbH & Co. KGaA (20.000 €)
- › EDAP TMS GmbH (1.500 €)
- › Ipsen Pharma GmbH (20.000 €)
- › Janssen - Cilag GmbH (20.000 €)
- › MSD Sharp & Dohme GmbH (6.000 €)
- › Pfizer Pharma GmbH (3.000 €)
- › Prostatype Genomics AB (3.000 €)

Eisai GmbH

The money will be spent for lease cost for the auditorium and technical equipment. All presentations and contents of the symposium are neutral without influences of companies and medical products. Conflicts of interests will be disclosed.

Scientific direction

Univ.-Prof. Dr. med. Dr. h.c. Axel Heidenreich

Director and Chairman, Department of Urology,
uro-oncology and robot assisted surgery
University hospital of Cologne
Kerpener Str. 62
50937 Cologne

Univ.-Prof. Dr. med. Martin Schostak

Department of Urology,
Medical Faculty University of Magdeburg
Leipziger Str. 44
39120 Magdeburg

Registration

Frank Jäger
Telefon: +49 (0) 221 478-82108
E-Mail: frank.jaeger@uk-koeln.de

Registration Fees

- › Urologist, Oncologist, Radiation Oncologist 180,- €
- › Residents 80,- €
- › Students free

Congress Venue

Radisson blu Hotel

Messe-Kreisel 3, 50679 Köln
Telefon: +49 (0) 221 277200
www.radissonblu.com/de/hotel-koeln